Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Feb 18, 2026
Reporting period
Not applicable
Filed with the SEC
Feb 21, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001437749-26-004948
Filed / recorded
Feb 21, 2026, 6:29 AM UTC
Added to OQRO
Oct 7, 2026, 5:52 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
PUMA BIOTECHNOLOGY, INC.
Issuer CIK
1401667
Ticker
PBYI
Reporting person
Alan H Auerbach
Relationship
Director, Officer, 10% owner
Officer title
President and CEO
Security
Stock Option (Right to Buy)
Table
Derivative (Table II)
Transaction date
Feb 18, 2026
Transaction code
A
Shares / units
227,474
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
227,474
Ownership form
Direct
Amendment
No
Footnotes from the filing
Subject to the Reporting Person's continued status as an Employee of the Company, the Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares of Common Stock subject thereto on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to acceleration in certain events.